Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial
Top Cited Papers
- 1 May 2020
- journal article
- research article
- Published by Elsevier in The Lancet Respiratory Medicine
- Vol. 8 (5) , 493-505
Abstract
No abstract availableKeywords
Funding Information
- European Commission Seventh Framework Programme (305404)
- Care-for-Rare Foundation, Eva Luise und Horst Köhler Stiftung and REGISTRY WAREHOUSE (777295)
This publication has 34 references indexed in Scilit:
- Clarithromycin therapy for patients with Cystic Fibrosis: A randomized controlled trialPediatric Pulmonology, 2012
- Azithromycin maintenance therapy in patients with cystic fibrosis: A dose advice based on a review of pharmacokinetics, efficacy, and side effectsPediatric Pulmonology, 2012
- Ventilation inhomogeneity in children with primary ciliary dyskinesiaThorax, 2011
- Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infectionJournal of Clinical Investigation, 2011
- Azithromycin for Prevention of Exacerbations of COPDNew England Journal of Medicine, 2011
- Reference values for paediatric pulmonary function testing: The Utrecht datasetRespiratory Medicine, 2011
- Lung Function in Patients with Primary Ciliary Dyskinesia: A Cross-Sectional and 3-Decade Longitudinal StudyAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Primary ciliary dyskinesia: a consensus statement on diagnostic and treatment approaches in childrenEuropean Respiratory Journal, 2009
- Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trialThorax, 2006
- Improvement of Survival in Patients with Diffuse Panbronchiolitis Treated with Low-dose ErythromycinAmerican Journal of Respiratory and Critical Care Medicine, 1998